Table 3.

Time from diagnosis to first b/ts/DMARDs treatment in PsA, failed treatments, and previous treatments in our PsA group

	PsA patients
	Overall, n 106
	Non-D2T n = 70 (66.1%)	D2T n = 36 (33.9%)	p value
Time from diagnosis to first b/ts DMARDs; median (IQR); months	24 (9–52)	54 (36–68)	< 0.01
Patients who failed b/ts DMARDs treatments, n (%)
≥ 1 b/ts DMARDs	30 (42.8)	36 (100)	< 0.01
≥ 2 b/ts DMARDs	6 (8.5)	36 (100)	< 0.01
≥ 3 b/ts DMARDs	3 (4.2)	24 (66.6)	< 0.01
Previous treatments
csDMARDs, n (%)	50 (71.4)	34 (94.4)
Anti-TNF, n (%)	30 (42.8)	30 (83.3)
Anti-IL12/23, n (%)	2 (2.8)	5 (13.8)
Anti-IL17, n (%)	14 (20)	19 (52.7)
Anti-PDE4	4 (5.7)	6 (16.6)